A Phase 1 interventional study of vobramitamab duocarmazine and lorigerlimab in Advanced Solid Tumor, Castration-Resistant Prostatic Cancer and Malignant Melanoma, sponsored by MacroGenics. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-14.
Sponsored by MacroGenics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 17 open to participants now, 23 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.
Among the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is the 30th largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2022, is one of 15 in phase 1, and was the 28th registered.
85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.
Browse Prostatic Neoplasms, Castration-Resistant studies →17 of the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18+ · Men only
Flare Therapeutics Inc. · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States
Ages 18–115 · Men only
Novartis Pharmaceuticals · Sites in United States
Ages 18–115 · Men only
T.O.A.D. Oncology SA · Sites in United States, Australia, Canada and 2 more countries
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 20 · Phase 3 8 · Phase 4 2
First in 2014; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 82 across 62 interventional studies indexed under Prostatic Neoplasms, Castration-Resistant.
Median enrollment 91 across the 42 interventional studies, 1,908 across the 6 observational. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 50 have an industry lead sponsor. The 10 most frequent:
MacroGenics is the lead sponsor of 42 studies on the registry; 4 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 11 (65%) have results posted.
MacroGenics has 4 studies filed under Prostatic Neoplasms, Castration-Resistant — fewer than ten, so there is no comparison to draw.
8 of the studies in Prostatic Neoplasms, Castration-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225946Phase 3Janssen Research & Development, LLCA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | 2027-11-19 |
| NCT07697989Novartis PharmaceuticalsPluvicto Real-world Investigation in Survival in Metastatic CRPC | 2027-01-31 |
| NCT07677254Novartis PharmaceuticalsA Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer | 2027-05-31 |
| NCT07677267Novartis PharmaceuticalsA Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan | 2027-05-31 |
| NCT05519449Janux TherapeuticsStudy of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled.
Vobramitamab duocarmazine and lorigerlimab are administered separately on Day 1 of every 4-week (28-day) cycle at the assigned dose for each cohort. Participants who do not meet criteria for study drug discontinuation may receive study drugs for up to 2 years.
Tumor assessments are performed every 8 weeks (± 7 days) for the initial 6 months on study drugs, then every 12 weeks (± 21 days) until progressive disease (PD).
Participants will be followed for safety throughout the study. .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
vobramitamab duocarmazine at dose level -1 and lorigerlimab intravenously (IV) every 4 weeks
Biological: vobramitamab duocarmazine · Biological: lorigerlimab
vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks
Biological: vobramitamab duocarmazine · Biological: lorigerlimab
vobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks
Biological: vobramitamab duocarmazine · Biological: lorigerlimab
vobramitamab duocarmazine at dose level 2 and lorigerlimab IV every 4 weeks
Biological: vobramitamab duocarmazine · Biological: lorigerlimab
vobramitamab duocarmazine at dose level 3 and lorigerlimab IV every 4 weeks
Biological: vobramitamab duocarmazine · Biological: lorigerlimab
vobramitamab duocarmazine at dose level 4 and lorigerlimab IV every 4 weeks
Biological: vobramitamab duocarmazine · Biological: lorigerlimab
maximum tolerated dose of vobramitamab duocarmazine and lorigerlimab IV every 4 weeks
Biological: vobramitamab duocarmazine · Biological: lorigerlimab
Vobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.
Also known as: MGC018
Lorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.
Also known as: MGD019
Number of participants with adverse events (AEs)
Time frame: Up to 2 years
Number of participants with serious adverse events (SAEs)
Time frame: Up to 2 years
Number of participants with AEs leading to study treatment discontinuation
Time frame: Up to 2 years
Mean maximum observed concentration (Cmax) of vobramitamab duocarmazine
Peak concentration of vobramitamab duocarmazine
Time frame: Throughout the study, up to 2 years
Mean maximum observed concentration (Cmax) of lorigerlimab
Peak concentration of lorigerlimab
Time frame: Throughout the study, up to 2 years
Mean time to maximum concentration (Tmax) of vobramitamab duocarmazine
Time at which peak concentration of vobramitamab duocarmazine is observed
Time frame: Throughout the study, up to 2 years
Mean time to maximum concentration (Tmax) of lorigerlimab
Time at which peak concentration of lorigerlimab is observed
Time frame: Throughout the study, up to 2 years
Mean area under the concentration-time curve during the dosing interval (AUCtau) of vobramitamab duocarmazine
Concentration of vobramitamab duocarmazine in the bloodstream during the 28-day dosing interval after dose administration
Time frame: Throughout the study, up to 2 years
Mean area under the concentration-time curve during the dosing interval (AUCtau) of lorigerlimab
Concentration of lorigerlimab in the bloodstream during the 28-day dosing interval after dose administration
Time frame: Throughout the study, up to 2 years
Mean trough concentration of vobramitamab duocarmazine
Concentration of vobramitamab duocarmazine at the end of a dosing interval
Time frame: Day 1 of each cycle (every 4 weeks) up to 2 years.
Mean trough concentration of lorigerlimab
Concentration of lorigerlimab at the end of a dosing interval
Time frame: Throughout the study, up to 2 years
Number of participants who develop anti-drug antibodies (ADA) to vobramitamab duocarmazine
Time frame: Throughout the study, up to 2 years
Number of participants who develop ADA to lorigerlimab
Time frame: Throughout the study, up to 2 years
Objective response rate (ORR)
Time frame: Assessed every 8 weeks for the first 6 months, then every 12 weeks for up to 2 years.
Median progression free survival (PFS)
PFS is defined as the time from the first dose date to the date of first documented PD or death from any cause, whichever occurs first.
Time frame: Assessed every 8 weeks for the first 6 months, then every 12 weeks. Survival status is assessed approximately every 12 weeks after the last dose of study treatment until withdrawal of consent, lost to follow up, death, or end of the study, up to 2 years.
Median duration of response (DoR)
DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented PD or death from any cause, whichever occurs first.
Time frame: Assessed every 8 weeks for the first 6 months, then every 12 weeks for up to 2 years.
Median overall survival (OS)
OS is defined as the time from the first dose date to the date of death from any cause.
Time frame: Survival status is assessed approximately every 12 weeks after the last dose of study treatment until withdrawal of consent, lost to follow up, death, or end of the study, up to 2 years
Median radiographic PFS (rPFS) for mCRPC
rPFS is defined as the time from the first dose of study drug to the first occurrence of radiographic PD of soft tissue lesions using RECIST v1.1, or appearance of ≥ 2 new bone lesions, or death from any cause
Time frame: Assessed every 8 weeks for the first 6 months, then every 12 weeks for up to 2 years.
Prostate-specific antigen (PSA) response rate for mCRPC
PSA response is defined as ≥ 50% decline from baseline in PSA with confirmation at least 3 weeks later.
Time frame: PSA is assessed every 4 weeks, up to 2 years while on treatment, then every 12 weeks for up to an additional 2 years in follow-up.
Best PSA percent change from baseline for mCRPC
Time frame: PSA is assessed every 4 weeks, up to 2 years while on treatment, then every 12 weeks for up to an additional 2 years in follow-up.
Median time to PSA progression for mCRPC
PSA progression is defined as an increase that is ≥ 25% and ≥ 2 ng/mL the baseline or lowest value observed, and which confirmed by a second value at least 3 weeks later.
Time frame: PSA is assessed every 4 weeks, up to 2 years while on treatment, then every 12 weeks for up to an additional 2 years in follow-up.
Median duration of PSA response for mCRPC
DoR of PSA is defined as the time from the date of initial PSA response to the date of first documented PSA progression or death from any cause, whichever occurs first.
Time frame: PSA is assessed every 4 weeks, up to 2 years while on treatment, then every 12 weeks for up to an additional 2 years in follow-up.
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2022 to primary completion in Jun 2025, 38 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vobramitamab duocarmazine · Lorigerlimab
Prostatic Neoplasms, Castration-Resistant →